NYSEMaterialsChemicals - SpecialtySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for FF yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Generate positive Adjusted EBITDA in 2026 | FutureFuel aims to generate positive adjusted EBITDA in 2026. | Intact | Adjusted EBITDA remains negative through FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: ““Second quarter Adjusted EBITDA increased to $11.8 million, an increase of more than $23 million versus the prior year, which supported improved free cash flow conversion in the period.”” “FutureFuel currently anticipates that favorable demand trends within its core Chemicals segment, together with an improved regulatory climate for its Biofuels segment, position the business to deliver positive Adjusted EBITDA (2) in the full-year 2026, excluding unrealized gains and losses on derivative instruments and inventory valuation adjustments.” |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 9, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a higher-risk execution story, not an established durable compounder, because FF is still loss-making. The long-term thesis is on watch: recent operations improved, but the full-year profitability goal is still pending and company quality has weakened.
The valuation model shows FF at a premium to peers, with a small expectations gap and medium confidence. The priced-in tag is unjustified, while fragility is low; these signals suggest the premium is not supported by a large expectations cushion, though the evidence does not specify exactly what the market assumes.
Near-term results have improved: revenue rose from $32.0 million in the first quarter of 2026 to $78.7 million in the second, and operating income moved from a loss to income. Chemicals revenue and utilization also increased, supporting management’s goal of positive Adjusted EBITDA in 2026, but the first-quarter loss and pending full-year result leave execution risk. Added Chemicals capacity is not expected online until early fiscal 2028.
The near-term swing factor is whether FF maintains guidance; a cut on the next call would be a meaningful negative. Over the multi-year view, the thesis depends on sustained improvement in Chemicals production and profitability, while sector bellwethers’ earnings and guidance could either support or weaken the Materials backdrop.
For the next 1 to 3 years, FF shows operational progress but remains a loss-making, elevated-risk business with a premium valuation and a thesis that still needs proof. The key test is whether recent improvements translate into the stated full-year profitability goal. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Maintain dividend payments at ~$0.01 per share | The company maintains dividend payments, signaling some financial discipline. | Intact | Dividend payments cease or fall below $0.01 per share | Dividend per share: $0.01 per share FY2026-Q2; GAAP. Published target: Dividend per share >= $0.01 per quarter. The target does not explicitly identify fiscal versus calendar quarters. Aug 10, 20260.01 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve meaningful revenue contributions in 2026 | A primary condition in FutureFuel Corp.'s published investment case. The stated target is Revenue >= $32M in 2026-Q1. | Intact | Revenue falls below $20M in any quarter of 2026 | Revenue: $78.726M FY2026-Q2; GAAP. Published target: Revenue >= $32M in 2026-Q1. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 10, 202678,726,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.